Lead Product(s) : 1,3 Butanediol
Therapeutic Area : Sleep
Study Phase : Phase I/ Phase II
Sponsor : HVMN Inc | KETONE-IQ
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Exogenous Ketones on Sleep Apnea
Details : 1,3 Butanediol is a Dietary Supplement drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Apnea, Obstructive.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : 1,3 Butanediol
Therapeutic Area : Sleep
Highest Development Status : Phase I/ Phase II
Sponsor : HVMN Inc | KETONE-IQ
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HS-10506
Therapeutic Area : Sleep
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase â… b/â…¡ Study of HS-10506 in Chinese Participants With Insomnia Disorder
Details : HS-10506 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : HS-10506
Therapeutic Area : Sleep
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AD313
Therapeutic Area : Sleep
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
Details : AD313 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Apnea, Obstructive.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : AD313
Therapeutic Area : Sleep
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZLT-101
Therapeutic Area : Sleep
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia
Details : 23 chronic insomnia patients treated with ZLT-101, Zelira's proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : ZLT-101
Therapeutic Area : Sleep
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable